Shalini Moningi

Closest collaborators

The 25 strongest of 58 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. Joseph M. Herman · 9 shared papers, 2014–2023 · strength 0.73
   • Paper Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, r… DOI 10.1016/s1470-2045(23)00478-3↗
   • Paper Maximizing Tumor Control and Limiting Complications With Stereotactic Body Radiation Therapy for Pancreatic Cancer. DOI 10.1016/j.ijrobp.2020.11.017↗
   • Paper EUS-guided placement of fiducial markers for the treatment of pancreatic cancer. DOI 10.1016/j.vgie.2019.05.007↗
2. Cullen M. Taniguchi · 6 shared papers, 2018–2023 · strength 0.63
   • Paper Contemporary use and outcomes of radiation and chemotherapy for unresectable pancreatic cancer. DOI 10.1016/j.ctro.2022.04.007↗
   • Paper Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, r… DOI 10.1016/s1470-2045(23)00478-3↗
   • Paper EUS-guided placement of fiducial markers for the treatment of pancreatic cancer. DOI 10.1016/j.vgie.2019.05.007↗
3. Eugene Jon Koay · 4 shared papers, 2018–2023 · strength 0.44
   • Paper Contemporary use and outcomes of radiation and chemotherapy for unresectable pancreatic cancer. DOI 10.1016/j.ctro.2022.04.007↗
   • Paper Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, r… DOI 10.1016/s1470-2045(23)00478-3↗
   • Paper Impact of Fiducial Marker Placement Before Stereotactic Body Radiation Therapy on Clinical Outcomes in Patients With Pa… DOI 10.1016/j.adro.2020.11.006↗
4. Manoop S. Bhutani · 4 shared papers, 2019–2023 · strength 0.41
   • Paper Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, r… DOI 10.1016/s1470-2045(23)00478-3↗
   • Paper EUS-guided placement of fiducial markers for the treatment of pancreatic cancer. DOI 10.1016/j.vgie.2019.05.007↗
   • Paper Impact of Fiducial Marker Placement Before Stereotactic Body Radiation Therapy on Clinical Outcomes in Patients With Pa… DOI 10.1016/j.adro.2020.11.006↗
5. Shane S. Neibart · 1 shared paper, 2024 · strength 0.36
   • Paper Stereotactic Body Radiation Therapy for Locally Advanced Pancreatic Cancer. DOI 10.2147/ceg.s341189↗
6. Krishan R. Jethwa · 1 shared paper, 2024 · strength 0.36
   • Paper Stereotactic Body Radiation Therapy for Locally Advanced Pancreatic Cancer. DOI 10.2147/ceg.s341189↗
7. Albert C. Koong · 4 shared papers, 2014–2022 · strength 0.36
   • Paper Contemporary use and outcomes of radiation and chemotherapy for unresectable pancreatic cancer. DOI 10.1016/j.ctro.2022.04.007↗
   • Paper Impact of Fiducial Marker Placement Before Stereotactic Body Radiation Therapy on Clinical Outcomes in Patients With Pa… DOI 10.1016/j.adro.2020.11.006↗
   • Paper Dose escalation for locally advanced pancreatic cancer: How high can we go? DOI 10.1016/j.adro.2018.07.008↗
8. Manisha Palta · 3 shared papers, 2020–2023 · strength 0.33
   • Paper Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, r… DOI 10.1016/s1470-2045(23)00478-3↗
   • Paper Maximizing Tumor Control and Limiting Complications With Stereotactic Body Radiation Therapy for Pancreatic Cancer. DOI 10.1016/j.ijrobp.2020.11.017↗
   • Paper Randomized, Double-Blinded, Placebo-controlled Multicenter Adaptive Phase 1-2 Trial of GC 4419, a Dismutase Mimetic, in… DOI 10.1016/j.ijrobp.2020.09.022↗
9. Lauren Elizabeth Colbert · 3 shared papers, 2018–2023 · strength 0.29
   • Paper Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, r… DOI 10.1016/s1470-2045(23)00478-3↗
   • Paper Randomized, Double-Blinded, Placebo-controlled Multicenter Adaptive Phase 1-2 Trial of GC 4419, a Dismutase Mimetic, in… DOI 10.1016/j.ijrobp.2020.09.022↗
   • Paper Dose escalation for locally advanced pancreatic cancer: How high can we go? DOI 10.1016/j.adro.2018.07.008↗
10. Ethan Bernard Ludmir · 2 shared papers, 2022–2023 · strength 0.26
    • Paper Contemporary use and outcomes of radiation and chemotherapy for unresectable pancreatic cancer. DOI 10.1016/j.ctro.2022.04.007↗
    • Paper Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, r… DOI 10.1016/s1470-2045(23)00478-3↗
11. Grace L. Smith · 2 shared papers, 2021–2022 · strength 0.24
    • Paper Contemporary use and outcomes of radiation and chemotherapy for unresectable pancreatic cancer. DOI 10.1016/j.ctro.2022.04.007↗
    • Paper Impact of Fiducial Marker Placement Before Stereotactic Body Radiation Therapy on Clinical Outcomes in Patients With Pa… DOI 10.1016/j.adro.2020.11.006↗
12. Joseph Abi Jaoude · 2 shared papers, 2021–2023 · strength 0.22
    • Paper Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, r… DOI 10.1016/s1470-2045(23)00478-3↗
    • Paper Impact of Fiducial Marker Placement Before Stereotactic Body Radiation Therapy on Clinical Outcomes in Patients With Pa… DOI 10.1016/j.adro.2020.11.006↗
13. Brian G. Czito · 2 shared papers, 2020–2023 · strength 0.21
    • Paper Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, r… DOI 10.1016/s1470-2045(23)00478-3↗
    • Paper Randomized, Double-Blinded, Placebo-controlled Multicenter Adaptive Phase 1-2 Trial of GC 4419, a Dismutase Mimetic, in… DOI 10.1016/j.ijrobp.2020.09.022↗
14. Jessica M. Frakes · 2 shared papers, 2020–2023 · strength 0.21
    • Paper Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, r… DOI 10.1016/s1470-2045(23)00478-3↗
    • Paper Randomized, Double-Blinded, Placebo-controlled Multicenter Adaptive Phase 1-2 Trial of GC 4419, a Dismutase Mimetic, in… DOI 10.1016/j.ijrobp.2020.09.022↗
15. Todd Anthony Aguilera · 2 shared papers, 2020–2023 · strength 0.21
    • Paper Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, r… DOI 10.1016/s1470-2045(23)00478-3↗
    • Paper Randomized, Double-Blinded, Placebo-controlled Multicenter Adaptive Phase 1-2 Trial of GC 4419, a Dismutase Mimetic, in… DOI 10.1016/j.ijrobp.2020.09.022↗
16. Rebecca S. Slack Tidwell · 2 shared papers, 2020–2023 · strength 0.21
    • Paper Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, r… DOI 10.1016/s1470-2045(23)00478-3↗
    • Paper Randomized, Double-Blinded, Placebo-controlled Multicenter Adaptive Phase 1-2 Trial of GC 4419, a Dismutase Mimetic, in… DOI 10.1016/j.ijrobp.2020.09.022↗
17. Sarah E. Hoffe · 2 shared papers, 2020–2023 · strength 0.21
    • Paper Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, r… DOI 10.1016/s1470-2045(23)00478-3↗
    • Paper Randomized, Double-Blinded, Placebo-controlled Multicenter Adaptive Phase 1-2 Trial of GC 4419, a Dismutase Mimetic, in… DOI 10.1016/j.ijrobp.2020.09.022↗
18. Ying Yuan · 2 shared papers, 2020–2023 · strength 0.21
    • Paper Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, r… DOI 10.1016/s1470-2045(23)00478-3↗
    • Paper Randomized, Double-Blinded, Placebo-controlled Multicenter Adaptive Phase 1-2 Trial of GC 4419, a Dismutase Mimetic, in… DOI 10.1016/j.ijrobp.2020.09.022↗
19. Shubham Pant · 2 shared papers, 2020–2023 · strength 0.21
    • Paper Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, r… DOI 10.1016/s1470-2045(23)00478-3↗
    • Paper Randomized, Double-Blinded, Placebo-controlled Multicenter Adaptive Phase 1-2 Trial of GC 4419, a Dismutase Mimetic, in… DOI 10.1016/j.ijrobp.2020.09.022↗
20. Ching-Wei David Tzeng · 2 shared papers, 2020–2023 · strength 0.21
    • Paper Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, r… DOI 10.1016/s1470-2045(23)00478-3↗
    • Paper Randomized, Double-Blinded, Placebo-controlled Multicenter Adaptive Phase 1-2 Trial of GC 4419, a Dismutase Mimetic, in… DOI 10.1016/j.ijrobp.2020.09.022↗
21. Irina Mihaela Cazacu · 2 shared papers, 2019–2021 · strength 0.20
    • Paper EUS-guided placement of fiducial markers for the treatment of pancreatic cancer. DOI 10.1016/j.vgie.2019.05.007↗
    • Paper Impact of Fiducial Marker Placement Before Stereotactic Body Radiation Therapy on Clinical Outcomes in Patients With Pa… DOI 10.1016/j.adro.2020.11.006↗
22. Gabriel Oliveira Sawakuchi · 2 shared papers, 2018–2023 · strength 0.20
    • Paper Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, r… DOI 10.1016/s1470-2045(23)00478-3↗
    • Paper Dose escalation for locally advanced pancreatic cancer: How high can we go? DOI 10.1016/j.adro.2018.07.008↗
23. Sharon Hermes Giordano · 1 shared paper, 2022 · strength 0.14
    • Paper Contemporary use and outcomes of radiation and chemotherapy for unresectable pancreatic cancer. DOI 10.1016/j.ctro.2022.04.007↗
24. Lauren M. Rosati · 3 shared papers, 2014–2016 · strength 0.13
    • Paper Lymphocyte-Sparing Effect of Stereotactic Body Radiation Therapy in Patients With Unresectable Pancreatic Cancer. DOI 10.1016/j.ijrobp.2015.11.026↗
    • Paper Stereotactic body radiation therapy in pancreatic cancer: the new frontier. DOI 10.1586/14737140.2014.952286↗
    • Paper The Role of Stereotactic Body Radiation Therapy for Pancreatic Cancer: A Single-Institution Experience. DOI 10.1245/s10434-014-4274-5↗
25. Matthew H. G. Katz · 1 shared paper, 2023 · strength 0.12
    • Paper Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, r… DOI 10.1016/s1470-2045(23)00478-3↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.